Bianco Fernando J, Scardino Peter T, Eastham James A
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Urology. 2005 Nov;66(5 Suppl):83-94. doi: 10.1016/j.urology.2005.06.116.
Radical prostatectomy (RP) disrupts the natural history of prostate cancer. However, it could be a significant source of long-term incontinence and potency morbidity. We studied the long-term cancer survival results and the probabilities of achieving ideal "trifecta" outcomes (cancer control, continence, and potency) after this surgical procedure. A total of 1746 intervention-naive patients with clinically localized newly diagnosed prostate cancer underwent RP with curative intent beginning in 1983. The mean follow-up time was 6 years (interquartile range, 3-9). The successive probabilities of achieving ideal trifecta outcomes for up to 24 months following RP versus experiencing biochemical recurrence were estimated using the cumulative incidence method. Additionally, long-term cancer control was assessed by preoperative and postoperative factors. Surgical excision controlled prostate cancer effectively in 1441 (83%) of the 1746 patients studied. At 5, 10, and 15 years, respectively, 82%, 77%, and 75% of patients were free from disease progression. Cancer-specific survival was 99%, 95% and 89%, respectively, at 5, 10, and 15 years. In men with disease progression, the 15-year probabilities of death from prostate cancer versus other causes were similar (32% and 33%, respectively). At 24 months, 60% of patients were potent, continent, and free of cancer, and 12% had experienced recurrence. Use of RP provided excellent long-term cancer control. At 15 years, only 11% of patients had died of prostate cancer. Cancer control was good even for patients with adverse prognostic features. The probability of death from cancer was similar to other causes after disease progression. By 2 years, 60% of men were continent, potent, and cancer free.
根治性前列腺切除术(RP)会改变前列腺癌的自然病程。然而,它可能是导致长期尿失禁和性功能障碍的重要原因。我们研究了该手术后的长期癌症生存结果以及实现理想“三连胜”结局(癌症控制、控尿和性功能)的概率。自1983年起,共有1746例初治的临床局限性新诊断前列腺癌患者接受了根治性意图的RP手术。平均随访时间为6年(四分位间距为3 - 9年)。使用累积发病率法估计了RP术后长达24个月实现理想三连胜结局与发生生化复发的连续概率。此外,通过术前和术后因素评估长期癌症控制情况。在1746例研究患者中,手术切除有效地控制了1441例(83%)患者的前列腺癌。在5年、10年和15年时,分别有82%、77%和75%的患者无疾病进展。5年、10年和15年时的癌症特异性生存率分别为99%、95%和89%。在疾病进展的男性患者中,15年因前列腺癌死亡与因其他原因死亡的概率相似(分别为32%和33%)。在24个月时,60%的患者性功能正常、控尿且无癌症,12%的患者出现复发。使用RP可实现出色的长期癌症控制。在15年时,仅11%的患者死于前列腺癌。即使对于具有不良预后特征的患者,癌症控制效果也良好。疾病进展后因癌症死亡的概率与因其他原因死亡的概率相似。到2年时,60%的男性控尿、性功能正常且无癌症。